Prime Medicine, Common Etf Profile
| PRME Etf | USD 1.95 0.06 2.99% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
Prime Medicine, is trading at 1.95 as of the 22nd of March 2025, a 2.99 percent decrease since the beginning of the trading day. The etf's lowest day price was 1.86. Prime Medicine, has more than 61 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of October 2022 | Category Healthcare | Classification Health Care |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange. The company has 131.16 M outstanding shares of which 18.06 M shares are at this time shorted by private and institutional investors with about 17.29 trading days to cover. More on Prime Medicine, Common
Moving together with Prime Etf
| 0.66 | A | Agilent Technologies | PairCorr |
| 0.82 | ME | 23Andme Holding | PairCorr |
| 0.77 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
Moving against Prime Etf
Prime Etf Highlights
| CEO and Presidentident | Keith Gottesdiener |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation Analysts covering Prime Medicine, report their recommendations after researching Prime Medicine,'s financial statements, talking to executives and customers, or listening in on Prime Medicine,'s conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Prime Medicine, Common. The Prime consensus assessment is calculated by taking the average forecast from all of the analysts covering Prime Medicine,. | |
| Total Current Liabilities | 37.96 Million |
| Total Stockholder Equity | 153.15 Million |
| Currency Code | USD |
| Fiscal Year End | December |
| Stock Based Compensation | 26.07 Million |
| Property Plant And Equipment Net | 71.56 Million |
| Begin Period Cash Flow | 55.07 Million |
| Net Debt | (141.68 Million) |
| Accounts Payable | 11.35 Million |
| Cash | 182.48 Million |
| Other Operating Expenses | 205.45 Million |
| Non Current Assets Total | 85.62 Million |
| Non Currrent Assets Other | 14.06 Million |
| Cash And Short Term Investments | 185.47 Million |
| 50 Day M A | 2.5913 |
| Code | PRME |
| Common Stock Shares Outstanding | 118.6 Million |
| Liabilities And Stockholders Equity | 297.51 Million |
| Country Name | USA |
| Net Interest Income | 3.52 Million |
| Capital Lease Obligations | 40.79 Million |
| E P S Estimate Next Year | (1.0249) |
| Investments | 68.46 Million |
| Other Current Assets | 26.41 Million |
| Free Cash Flow | (130.16 Million) |
| Net Invested Capital | 153.15 Million |
| E P S Estimate Current Year | (1.155) |
| Depreciation | 6.13 Million |
| Operating Income | (202.47 Million) |
| 200 Day M A | 3.9177 |
Prime Medicine, Common [PRME] is traded in USA and was established 2015-11-11. Prime Medicine, is listed under Biotechnology category by Fama And French industry classification. The fund is listed under Health Care category and is part of Biotechnology family. Prime Medicine, Common at this time have 297.51 M in assets. , while the total return for the last 3 years was 3.82%.
Prime Medicine, Common currently holds about 146.66 M in cash with (122.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Prime Medicine, Probability Of Bankruptcy
Top Prime Medicine, Common Etf Constituents
| KRC | Kilroy Realty Corp | Stock | Real Estate | |
| AKR | Acadia Realty Trust | Stock | Real Estate | |
| HPP | Hudson Pacific Properties | Stock | Real Estate | |
| AVB | AvalonBay Communities | Stock | Real Estate | |
| BXP | Boston Properties | Stock | Real Estate | |
| EQIX | Equinix | Stock | Real Estate | |
| EQR | Equity Residential | Stock | Real Estate | |
| SPG | Simon Property Group | Stock | Real Estate |
Prime Medicine, Major Institutional Holders
| Instituion | Recorded On | Shares | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 1.6 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.5 M | |
| State Street Corp | 2024-12-31 | 1.2 M | |
| Baker Bros Advisors Lp | 2024-12-31 | 1 M | |
| Westwood Holdings Group Inc | 2024-12-31 | 883.1 K | |
| Greenwich Wealth Management Llc | 2024-12-31 | 774 K | |
| Farallon Capital Management, L.l.c. | 2024-12-31 | 750 K | |
| Ecor1 Capital, Llc | 2024-12-31 | 700 K | |
| Northern Trust Corp | 2024-12-31 | 544.9 K | |
| Alphabet Inc | 2024-12-31 | 15.1 M | |
| Ark Investment Management Llc | 2024-12-31 | 5.2 M |
Prime Medicine, Common Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Prime Medicine,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (0.07) | |||
| Treynor Ratio | 2.31 |
Prime Medicine, Against Markets
Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.